Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1)

British Journal of Pharmacology

Volumn 136, Issue 3, 2002, Pages 421-433

  MacKenzie, Simon J ^a   Baillie, George S ^a   McPhee, Ian ^a   Mac Kenzie, Carolynn ^a   Seamons, Rachael ^b   McSorley, Theresa ^a   Millen, Jenni ^a   Beard, Matthew B ^a   van Heeke, Gino ^b   Houslay, Miles D ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

PDE4 cAMP phosphodiesterase; Phosphorylation; PKA; Protein kinase A; Rolipram

Indexed keywords

3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ANTISERUM; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; ISOENZYME; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; ROLIPRAM; SERINE; ALANINE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; FORSKOLIN; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE IV INHIBITOR;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CELL STRAIN COS1; CHEMOLUMINESCENCE; ENZYME ACTIVATION; FEMALE; GENETICS; IMMUNOLOGY; METABOLISM; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; RABBIT; SITE DIRECTED MUTAGENESIS; ANIMAL CELL; DEPHOSPHORYLATION; DNA FLANKING REGION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IMMUNOBLOTTING; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; SECOND MESSENGER; UPSTREAM CONSERVED REGION 1;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMINO ACID SEQUENCE; ANIMALS; CHEMILUMINESCENT MEASUREMENTS; CONSERVED SEQUENCE; COS CELLS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME ACTIVATION; FEMALE; IMMUNE SERA; ISOENZYMES; MUTAGENESIS, SITE-DIRECTED; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; RABBITS; ROLIPRAM; SERINE; ANIMAL; CHEMILUMINESCENCE; SUPPORT, NON-U.S. GOV'T;

EID: 0036016114     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704743     Document Type: Article

References (61)

1. Activation and selective inhibition of a cyclic AMP-specifc phosphodiesterase, PDE-4D3
2. Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving Extracellular Signal Regulated Kinase (ERK)
3. Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases
4. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD)
5. UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase (PDE4) family form a discrete module via electrostatic interactions
6. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
7. Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: A diverse family of regulatory enzymes
8. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs
9. Characterisation of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene
10. Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts: Characterization of a novel tissue-specific isoform, RNPDE4A8
11. Protein determination in biological samples
12. Phosphodiesterase IV inhibitors: Structural diversity and therapeutic potential in asthma
13. AKAPs: From structure to function
14. The molecular biology of cyclic nucleotide phosphodiesterases
15. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module
16. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits a net increase in cyclic AMP phosphodiesterase activity by upregulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as downregulating a novel PDE4A splice variant
17. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here?
18. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors
19. Insulin exerts actions through a distinct species of guanine nucleotide regulatory protein: Inhibition of adenylate cyclase
20. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase, HSPDE4D3 by phosphorylating it at Ser579
21. cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: Generation of a molecular model
22. PDE4 cAMP-specific phosphodiesterases
23. Tailoring cAMP signalling responses through isoform multiplicity
24. The multi-enzyme PDE4 cyclic AMP specific phosphodiesterase family: Intracellular targeting, regulation and selective inhibition by compounds exerting anti-inflammatory and anti-depressant actions
25. The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3 interaction domain by caspase-3: Consequences for altered intracellular distribution
26. Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cyclic AMP specific phosphodiesterase, HSPDE4B3
27. The postsynaptic density: A subcellular anchor for signal transduction enzymes
28. Protein kinase A regulation of cAMP phosphodiesterase expression in rat skeletal myoblasts
29. Cleavage of structural proteins during assembly of the head of bacteriophage T4
30. Activation of the cAMP-specific phosphodiesterase PDE4D3 by phosphorylation: Identification and function of an inhibitory domain
31. ERK2 MAP kinase binding, phosphorylation and regulation of PDE4D cAMP specific phosphodiesterases: The involvement of C-terminal docking sites and N-terminal UCR regions
32. The action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of CREB and p38 MAP kinase in U937 monocytic cells
33. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families
34. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE 3 gene family)
35. An intrinsic and a peripheral protein constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes
36. Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family
37. Association with the src family tyrosyl kinase lyn triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B: Consequences for rolipram inhibition
38. Short term feedback regulation of cAMP in FRTL-5 thyroid cells: Role of PDE4D3 phosphodiesterase activation
39. Molecular cloning and expression of a human phosphodiesterase 4C
40. Molecular cloning and characterization of the novel cAMP specific phosphodiesterase, PDE4A10
41. Asthma therapy for the 21st century
42. PDE isoenzymes as targets for anti-asthma drugs
43. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase: Involvement of serine 54 in the enzyme activation
44. The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation
45. The ratPDE3/1Vd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase
46. 2-adrenoreceptor desensitization
47. Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram
48. Identification and characterization of the type-IV A cyclic AMP- specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum
49. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions
50. Proposal for pharmacologically distinct conformers of PDE4
51. The role of phosphodiesterase enzymes in allergy and asthma
52. The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP
53. Glucagon, vasopressin and angiotensin all elicit a rapid, transient increase in hepatocyte protein kinase C activity
54. Phosphodiesterase 4D and protein kinase A type II constitute a signaling unit in the centrosomal area
55. Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and function
56. Multiple cyclic nucleotide phosphodiesterase activities from rat brain
57. Co-transfection with protein kinase D confers phorbolester-mediated inhibition on glucagon-stimulated cAMP accumulation in COS cells transfected to overexpress glucagon receptors
58. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents
59. Regulation of distinct cyclic AMP-specific phosphodiesterase (PDE4) isozymes in human monocytic cells
60. Characterization of an intronic promoter of a cyclic adenosine 3′, 5′- monophosphate (cAMP) - Specific phosphodiesterase gene that confers hormone and cAMP inducibility
61. Atomic structure of PDE4: Insights into phosphodiesterase mechanism and specificity